Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 685509 in Healthy Male Subjects

Trial Profile

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 685509 in Healthy Male Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Dec 2017

At a glance

  • Drugs BI 685509 (Primary)
  • Indications Kidney disorders
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 12 Dec 2017 Planned End Date changed from 11 Dec 2017 to 25 Jan 2018.
    • 12 Dec 2017 Planned primary completion date changed from 11 Dec 2017 to 25 Jan 2018.
    • 18 Oct 2017 Planned End Date changed from 7 Nov 2017 to 11 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top